Publications by authors named "Camden L Esancy"
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Hematol Oncol Clin North Am
April 2019
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 tumor-infiltrating lymphocytes.
View Article and Find Full Text PDFPurpose: Biomarkers are needed to stratify patients with stage II-III melanoma for clinical trials of adjuvant therapy because, while immunotherapy is protective, it also confers the risk of severe toxicity. We previously defined and validated a 53-immune gene melanoma immune profile (MIP) predictive both of distant metastatic recurrence and of disease-specific survival (DSS). Here, we test MIP on a third independent population.
View Article and Find Full Text PDFArticle Synopsis
- The study emphasizes the need for improved analysis methods of the tumor microenvironment (TME) to better stratify melanoma patients for immunotherapy, moving beyond traditional TIL analysis.
- Researchers utilized quantitative multiplex immunofluorescence (qmIF) to evaluate the proximity of cytotoxic lymphocytes (CTLs) and macrophages in melanoma tumors, finding that CTLs were significantly closer to activated macrophages than to nonactivated ones.
- Results indicated that higher CTL density and lower macrophage density in the tumor stroma correlated with better disease-specific survival, suggesting that the CTL/macrophage ratio could serve as a potential biomarker for predicting patient outcomes in melanoma treatment.